Sapropterin Dihydrochloride (Kuvan)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Phenylketonuria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.
Product first approved 2008EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Phenylketonuria
NCT00838435 · BioMarin Pharmaceutical
2009-02 – 2018-09-14 · Phenylketonuria
What this study did
NCT01732471 · Merck KGaA, Darmstadt, Germany
2012-11 – 2013-10 · Phenylketonuria
What this study did
NCT01114737 · BioMarin Pharmaceutical
2010-08 – 2013-03 · Phenylketonuria
What this study did
NCT00332189 · BioMarin Pharmaceutical
2006-07 – 2009-08 · Phenylketonuria
What this study did
NCT00225615 · BioMarin Pharmaceutical
2005-11 – 2006-06 · Phenylketonurias
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT01456286 · Fundacion Clinic per a la Recerca Biomédica
2011-10 – 2013-10 · Liver Cirrhosis, Portal Hypertension
What this study did
NCT00935753 · University of California, San Diego
2009-04 – 2010-02 · Behavioral Manifestations of Lesch-Nyhan Disease
What this study did
NCT00432822 · Orphanetics Pharma Entwicklungs GmbH
— · Phenylalanine Hydroxylase Deficiencies
What this study did
Phase 2 (21)
Phenylketonuria
NCT01977820 · BioMarin Pharmaceutical
2014-02 – 2014-11 · Phenylketonuria
What this study did
NCT01395394 · Emory University
2011-06 – 2013-06 · Phenylketonuria
What this study did
NCT00841100 · University of Miami
2008-12 – 2011-07-19 · Phenylketonuria
What this study did
NCT00260000 · The Kennedy Institute-National Eye Clinic
2005-04 – 2005-12 · Phenylketonuria
What this study did
NCT00104260 · BioMarin Pharmaceutical
2004-12 – 2005-11 · Phenylketonurias
What this study did
Other / comorbidity
NCT02947750 · Emory University
2016-10 – 2027-04-30 · Renal Insufficiency, Chronic
What this study did
NCT06396637 · Sun Yat-sen University
2024-04-30 – 2025-04-30 · Pancreatic Adenocarcinoma Metastatic
What this study did
NCT05138887 · West China Second University Hospital
2022-03-01 – 2024-03-01 · Radiation Enteritis
What this study did
NCT04054973 · University of Massachusetts, Worcester
2019-09-11 – 2021-12-31 · Schizo Affective Disorder, Schizophrenia
What this study did
NCT02774226 · Augusta University
2015-09 – 2018-07-30 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01772758 · Augusta University
2011-08 – 2016-06-21 · Cystic Fibrosis
What this study did
NCT00919295 · Mahidol University
2008-12 – 2011-12 · Fibromyalgia Syndrome
What this study did
NCT00850070 · The Children's Health Council
2009-03 – 2011-10 · Autistic Disorder
What this study did
NCT00355264 · BioMarin Pharmaceutical
2006-08 – 2009-06 · Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric
What this study did
NCT00445978 · BioMarin Pharmaceutical
2007-05 – 2009-06 · Sickle Cell Disease
What this study did
NCT00802893 · Johns Hopkins University
2008-12 – 2009-05 · Isolated Systolic Hypertension, Endothelial Dysfunction
What this study did
NCT00532844 · BioMarin Pharmaceutical
2007-09 – 2009-03 · Endothelial Dysfunction
What this study did
NCT00423280 · University of Oxford
2006-11 – 2009-02 · Coronary Artery Disease
What this study did
NCT00403494 · BioMarin Pharmaceutical
2006-12 – 2009-01 · Intermittent Claudication
What this study did
NCT00325962 · BioMarin Pharmaceutical
2006-05 – 2008-12 · Hypertension
What this study did
NCT00625820 · University of Michigan
2008-05 – 2008-09 · Kidney Disease, Albuminuria
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT02530996 · VA Office of Research and Development
2016-01-01 – 2019-12-31 · Rheumatologic Disease
What this study did
NCT01425528 · University of Utah
2011-08 – 2013-08 · GTP Cyclohydrolase Deficiency
What this study did
Phase 1 (11)
Phenylketonuria
NCT07255599 · Sohag University
2025-09-01 – 2026-09-01 · Phenylketonuria (PKU)
What this study did
NCT00244218 · The University of Texas Medical Branch, Galveston
2005-04 – 2015-01 · Phenylketonuria
What this study did
NCT00789568 · BioMarin Pharmaceutical
2008-10 – 2009-10 · Phenylketonuria
What this study did
Other / comorbidity
NCT06312748 · VA Office of Research and Development
2021-05-19 – 2030-09-30 · Heart Failure With Preserved Ejection Fraction, Inflammation
What this study did
NCT02966665 · D. Walter Wray
2008-09 – 2030-08 · Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
What this study did
NCT06987773 · APR Applied Pharma Research s.a.
2025-08-20 – 2025-10-28 · Bioequivalence
What this study did
NCT03136029 · VA Office of Research and Development
2018-06-01 – 2025-07-31 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT06481709 · APR Applied Pharma Research s.a.
2024-07-30 – 2024-08-31 · Bioavailability
What this study did
NCT05299203 · West China Hospital
2022-05 – 2023-05 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT03680573 · The University of Texas at Arlington
2018-01-08 – 2018-05-05 · Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
What this study did
NCT00435331 · Vanderbilt University
2008-03 – 2008-10 · Pulmonary Arterial Hypertension
What this study did
Phase 4 (6)
Phenylketonuria
NCT01965912 · BioMarin Pharmaceutical
2013-10 – 2023-01-04 · Phenylketonuria
What this study did
NCT04227080 · Taipei Veterans General Hospital, Taiwan
2020-06 – 2022-06 · Pku Phenylketonuria, PAH Deficiency
What this study did
NCT02677870 · University Hospitals Cleveland Medical Center
2018-01-22 – 2019-01-01 · Phenylketonuria
What this study did
NCT01617070 · University of Southern California
2012-05 – 2014-12 · Phenylketonuria (PKU)
What this study did
NCT01082328 · Merck KGaA, Darmstadt, Germany
2010-05 – 2012-05 · Phenylketonuria
What this study did
Other / comorbidity
NCT03493412 · University of Nebraska
2019-07-01 – 2019-10-01 · Peripheral Artery Disease, Peripheral Arterial Disease
What this study did
Early phase / not applicable (9)
Phenylketonuria
NCT01806051 · Dr. Linda Randolph
2013-03 – 2014-05 · Phenylketonuria (PKU)
What this study did
NCT01412437 · Children's National Research Institute
2011-04 – 2012-12 · PKU
What this study did
NCT01541397 · The University of Texas Health Science Center, Houston
2011-06 – 2012-08 · Hyperphenylalaninemia, Phenylketonuria
What this study did
NCT00986973 · Children's Hospital of Philadelphia
2010-03 – 2011-09 · Phenylketonuria
What this study did
Other / comorbidity
NCT07574034 · Gregor Andelfinger
2026-07-15 – 2030-06-01 · Multisystemic Smooth Muscle Dysfunction Syndrome
What this study did
NCT02353312 · Providence VA Medical Center
2015-03 – 2018-12 · Heart Failure, Cardiovascular Disease
What this study did
NCT01398943 · Augusta University
2010-09 – 2015-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01135186 · Stanford University
2010-05 – 2012-11 · Gastroparesis
What this study did
NCT01141595 · The University of Texas Health Science Center, Houston
2010-07 – 2011-09 · Autism Spectrum Disorder
What this study did

Competitive landscape

Other Phenylalanine hydroxylase (PAH) drugs

Sepiapterin. Compare all 2 Phenylalanine hydroxylase (PAH) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Phenylketonuria: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sapropterin Dihydrochloride (Kuvan): this drugApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signal
NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36)
NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009).
Pegvaliase (PALYNZIQ)ApprovedProtein / enzyme therapeuticPhenylalanine ammonia lyase (enzyme substitution)Weak signalFeatured results are safety only in this race
SepiapterinApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signalNo reviewed efficacy summary in this indication
BEAM-304
—(overall)
Gene therapy / editingPAH gene (phenylalanine hydroxylase)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sapropterin Dihydrochloride (Kuvan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 2Renal Insufficiency, ChronicRecruiting
Est. primary completion 2027-04-30 · NCT02947750 · CT.gov ↗
What to watch
2028 (2)
June 2028 (1)
Early phase / not applicableMultisystemic Smooth Muscle Dysfunction SyndromeRecruiting
Est. primary completion 2028-06-01 · NCT07574034 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Heart Failure With Preserved Ejection Fraction, InflammationRecruiting
Est. primary completion 2028-09-30 · NCT06312748 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 1Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, HypertensionRecruiting
Est. primary completion 2030-08 · NCT02966665 · CT.gov ↗
What to watch

See the full readout calendar ↗